Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 13Completed 5Active not recruiting 4Not yet recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 7Recurrence 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 17Rituximab 14Cytarabine 9Peripheral Blood Stem Cell Transplantation 7Melphalan 7Etoposide 7Filgrastim 6Dexamethasone 6fludarabine phosphate 5fludarabine 5Radiotherapy 5Cyclosporine 5Carmustine 5ibrutinib 4Vincristine 4Prednisone 4Lenalidomide 4Doxorubicin 4Bortezomib 4Sensitivity and Specificity 3R-CHOP protocol 3Mycophenolic Acid 3Interferon-alpha 3Indium 3Cisplatin 3Busulfan 3Bendamustine Hydrochloride 3Antilymphocyte Serum 3Antigens, CD19 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Mantle-Cell × zanubrutinib × Clear all
NCT05504603 2022-08-17

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡